GlassScriptPhysician profile
Shanice Mckenzie
NPI 1548899297
$3,973.17
in general payments reported to CMS, 2019-2025
14 companies · $771 in 2025
The $771 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $257 · 2023: $1,685 · 2024: $1,136 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,591.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,207.08 | 2023-2025 | |
| Dermavant Sciences, INC. | $645.20 | 2023-2024 | Vtama |
| Genzyme Corporation | $536.96 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.74 | 2022-2024 | |
| Ucb, INC. | $458.86 | 2023-2025 | Bimzelx |
| Incyte Corporation | $281.10 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $74.11 | 2023-2024 | Dysport |
| Janssen Biotech, INC. | $64.54 | 2025 | Tremfya |
| Pierre Fabre Pharmaceuticals, INC. | $61.95 | 2023 | Hemangeol |
| Regeneron Healthcare Solutions, INC. | $56.69 | 2025 | Libtayo |
| Revance Therapeutics, INC. | $32.10 | 2024 | Daxi |
| Sumitomo Pharma America, INC. | $27.10 | 2025 | Gemtesa |
| Amgen INC. | $19.55 | 2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $14.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanice Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.